Key result
Ristocetin at concentrations of 0.5 mg/ml or more significantly reduced the electrophoretic mobility of platelets, an effect markedly enhanced by the presence of normal plasma containing von Willebrand factor.
Effect estimate: 5.3% reduction
Absolute Event Rate: -0.789% vs -0.833%
p-value: p=<0.001
Ristocetin facilitates platelet agglutination by reducing net surface charge and enabling the binding of von Willebrand factor, which acts as a bridge between platelets.
No takes yet. Share an insight, caveat, or question.
May inform ristocetin-based platelet assays; leaves open human translation from animal data.
Barry S. Coller (1978) studied Platelet agglutination. Ristocetin and von Willebrand factor vs. Buffer alone was evaluated on Platelet electrophoretic mobility (5.3% reduction, p=<0.001). Ristocetin at concentrations of 0.5 mg/ml or more significantly reduced the electrophoretic mobility of platelets, an effect markedly enhanced by the presence of normal plasma containing von Willebrand factor.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: